Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer

Yoshida, Shigeaki; Miyata, Yoshinori; Ohtsu, Atsushi; Boku, Narikazu; Shirao, Kuniaki; Shimada, Yasuhiro

doi:10.1007/pl00011706

Cited by 29 publications

(18 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 and 4). These results suggested that the evaluation of primary lesions according to the Japanese criteria was a valid method for the assessment of response, confi rming the results of previous studies [3][4][5][6]. Our results suggest that the response of primary lesions to chemotherapy should be evaluated if possible in studies of gastric cancer.…”

Section: Discussionsupporting

confidence: 78%

See 1 more Smart Citation

Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy

et al. 2010

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 78%

“…The usefulness of the Japanese criteria has also been reviewed by Kiyohashi et al [4], Yoshida et al [5], and Ohtsu et al [6].…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy

et al. 2010

View full text Add to dashboard Cite

“…Moreover, antitumor effects may be assessed only in the primary tumor in most of them. 15 A previous phase II study of CPT-11 in combination with CDDP provided insufficient information with respect to responses in primary sites in patients with peritoneal dissemination, because the number of chemotherapy-naive patients was too small.…”

Section: Introductionmentioning

confidence: 99%

Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

et al. 2001

Self Cite

View full text Add to dashboard Cite

“…The conventional primary endpoint of a phase II study is RR; however, in AGC, RR correlates poorly with survival [28,29]. We chose OS as the primary endpoint in this study for this reason [13,28,29], and also because evidence for non-measurable, time-dependent effects, e.g.…”

Section: Discussionmentioning

confidence: 99%

A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status

Rha

Jeung

et al. 2009

Oncology

View full text Add to dashboard Cite

Purpose: We investigated the efficacy and safety of weekly paclitaxel monotherapy in previously treated patients with advanced gastric cancer (AGC) and poor performance status (PS) according to the Eastern Cooperative Oncology Group (ECOG). Patients and Methods: Patients with evaluable disease who failed at least one previous chemotherapy and had a PS of 2–3, received paclitaxel 70 mg/m² on days 1, 8 and 15 every 4 weeks. Results: The median overall survival (OS) was 5.5 months (95% confidence interval, CI, 3.3–7.8) and progression-free survival was 2.1 months (95% CI, 1.2–3.0). The overall response rate was 3.8% and the disease control rate was 25.0%. Treatment-related toxicities were tolerable. OS was 7.1 (95% CI, 5.4–9.5) and 3.7 months (95% CI, 2.1–5.3) for patients with PS-ECOG 2 and 3, respectively (p < 0.001). When evaluated according to the previous treatment, OS was 5.1 (95% CI, 3.3–7.0) and 6.5 months (95% CI, 3.8–9.3) for patients receiving two and three or more lines of treatment, respectively (p = 0.815). With multivariate analysis, PS was a significant factor for OS. Conclusion: Survival in patients treated with weekly paclitaxel monotherapy was comparable to other second- or third-line chemotherapies for AGC, with acceptable toxicities in previously treated patients with poor PS.

show abstract

Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer

Cited by 29 publications

References 4 publications

Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy

Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy

Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status

Contact Info

Product

Resources

About